BTG reports robust trading postmerger
03 April 2009
Sita Shah
Please Login to read the full article.
03 April 2009
Sita Shah
sita.shah@informa.com
BTG expects its fiscal 2008 revenues to exceed those of 2007 and announced that the integration of its Protherics acquisition was proceeding to schedule.
It forecasts higher annualised sales revenues from its crotalid antivenom CroFab and DigiFab, a digoxin antidote, for the year ended March...
Please Login to read the full article.
RELATED CONTENT
NEWS
- BTG swells antidote portfolio with Wellstat's 5-FU overdose candidate
- Tekturna's future looks dim as Novartis cuts 1,960 jobs
- Adverse effects cast doubt over Sanofi's Taxotere follow on Jevtana, says NICE
- Allozyne finds route to going public via merger with troubled Poniard and its anticancer picoplatin
COMMENT
Other Informa Comment
EVENTS
09 February 2012
London
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
